Literature DB >> 10082254

Serum melatonin kinetics and long-term melatonin treatment for sleep disorders in Rett syndrome.

A Miyamoto1, J Oki, S Takahashi, A Okuno.   

Abstract

We studied the circadian rhythm of serum melatonin levels in two patients with classical Rett syndrome having severe sleep disorders; serum melatonin levels were measured before and during melatonin treatment using radioimmunoassay. Patient 1 had a free-running rhythm of sleep-wake cycle from 3 years of age. At the age of 4 years, the peak time of melatonin was delayed 6 h compared to normal control and the peak value was at the lower limit. Patient 2 had a fragmented sleep pattern accompanied by night screaming from 1 year and 6 months of age. At the age of 10 years, the peak time of melatonin secretion was normal but the peak value was at the lower limit. These patients were given 5 mg melatonin orally prior to bedtime. Exogenous melatonin dramatically improved the sleep-wake cycle in patient 1. In patient 2, exogenous melatonin showed a hypnotic effect but early morning awakenings occurred occasionally. When melatonin treatment was stopped, the sleep disorders recurred and re-administration of 3 mg melatonin was effective in both patients. The effect was maintained over 2 years without any adverse effects. These findings suggests that sleep disorders in patients with Rett syndrome may relate with an impaired secretion of melatonin.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10082254     DOI: 10.1016/s0387-7604(98)00072-2

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  11 in total

1.  Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial.

Authors:  Barry Wright; David Sims; Siobhan Smart; Ahmed Alwazeer; Ben Alderson-Day; Victoria Allgar; Clare Whitton; Heather Tomlinson; Sophie Bennett; Jenni Jardine; Nicola McCaffrey; Charlotte Leyland; Christine Jakeman; Jeremy Miles
Journal:  J Autism Dev Disord       Date:  2011-02

2.  Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment.

Authors:  Rüdiger Hardeland
Journal:  Aging Dis       Date:  2011-02-10       Impact factor: 6.745

3.  An open-label study of controlled-release melatonin in treatment of sleep disorders in children with autism.

Authors:  F Giannotti; F Cortesi; A Cerquiglini; P Bernabei
Journal:  J Autism Dev Disord       Date:  2006-08

Review 4.  Evaluation of current pharmacological treatment options in the management of Rett syndrome: from the present to future therapeutic alternatives.

Authors:  Christopher A Chapleau; Jane Lane; Lucas Pozzo-Miller; Alan K Percy
Journal:  Curr Clin Pharmacol       Date:  2013-11

Review 5.  Melatonin in children with autistic spectrum disorders: recent and practical data.

Authors:  C Doyen; D Mighiu; K Kaye; C Colineaux; C Beaumanoir; Y Mouraeff; C Rieu; P Paubel; Y Contejean
Journal:  Eur Child Adolesc Psychiatry       Date:  2011-02-26       Impact factor: 4.785

Review 6.  Medication for sleep-wake disorders.

Authors:  G Stores
Journal:  Arch Dis Child       Date:  2003-10       Impact factor: 3.791

Review 7.  Advances in the research of melatonin in autism spectrum disorders: literature review and new perspectives.

Authors:  Sylvie Tordjman; Imen Najjar; Eric Bellissant; George M Anderson; Marianne Barburoth; David Cohen; Nemat Jaafari; Olivier Schischmanoff; Rémi Fagard; Enas Lagdas; Solenn Kermarrec; Sophie Ribardiere; Michel Botbol; Claire Fougerou; Guillaume Bronsard; Julie Vernay-Leconte
Journal:  Int J Mol Sci       Date:  2013-10-14       Impact factor: 5.923

Review 8.  The relationship between sleep and behavior in autism spectrum disorder (ASD): a review.

Authors:  Simonne Cohen; Russell Conduit; Steven W Lockley; Shantha Mw Rajaratnam; Kim M Cornish
Journal:  J Neurodev Disord       Date:  2014-12-11       Impact factor: 4.025

9.  Why do seizures occur when they do? Situations perceived to be associated with increased or decreased seizure likelihood in people with epilepsy and intellectual disability.

Authors:  Josephine L Illingworth; Peter Watson; Howard Ring
Journal:  Epilepsy Behav       Date:  2014-09-16       Impact factor: 2.937

10.  The feasibility of using actigraphy to characterize sleep in Rett syndrome.

Authors:  Alyssa M Merbler; Breanne J Byiers; John J Garcia; Timothy J Feyma; Frank J Symons
Journal:  J Neurodev Disord       Date:  2018-02-27       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.